Ultragenyx Pharmaceutical Inc. (RARE) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Ultragenyx Pharmaceutical Inc. on April 22, 2022, covering events occurring on April 18 and April 19, 2022. The filing addresses changes to the composition of the Company's Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and director appointments.
Material Changes
- Director Departure: William Aliski notified the Company on April 18, 2022, that he will not stand for re-election at the 2022 Annual Meeting. His departure is for personal reasons and is not related to any disagreement with the Company.
- Director Appointment: On April 19, 2022, the Board appointed Amrit Ray, M.D., as a Class III director effective immediately. Dr. Ray was also appointed to the Research and Development Committee.
- Board Composition: The size of the Board was fixed at ten directors, comprising three Class I, three Class II, and four Class III directors.
Compensation and Governance Details
In connection with his appointment, Dr. Ray received compensation consistent with the Non-Employee Director Compensation Policy, including:
- 5,120 restricted stock units.
- A stock option to purchase up to 9,525 shares of common stock with an exercise price of $78.10 (the closing price on the Effective Date).
- An indemnification agreement requiring the Company to indemnify Dr. Ray to the fullest extent permitted under Delaware law.
Dr. Ray's background includes roles as Chief Patient Officer at Biohaven Pharmaceuticals, Senior Adviser to Bain Capital Life Sciences, and various executive leadership positions at Pfizer and Johnson & Johnson.
Investor Verification Checklist
- Verify the exact date of the 2022 Annual Meeting to confirm the end of William Aliski's term.
- Review the Company's Non-Employee Director Compensation Policy for details on standard director remuneration.
- Confirm the current total number of directors on the Board following the appointment of Dr. Ray.
- Check for any subsequent filings regarding the election results at the 2022 Annual Meeting.